13 AUGUST

Exceeding Site Identification Targets Across Three Recent Clinical Trial Studies

Overview
Site identification is the first and most critical deliverable from a CRO. Without an appropriate site, there is no patient recruitment, and without patients, there is no study.


PharmaSols has a proven ability to identify sites, even in challenging environments. While New Zealand and Australia have relatively low rates of transmission of COVID-19, our sites are still able to operate under all levels of lockdown as clinical trials have been classed as essential work. Additionally, sites can facilitate remote monitoring and telehealth capabilities due to the world-class research infrastructure and the uptake of technology.


In three recent studies, all of which were in the pre-award feasibility stage, we identified sites and confirmed capabilities and availability. Our expert team was tasked with identifying 18 sites across the three studies.

Challenges
Ophthalmology study


Typically it is challenging to recruit sites for this particular therapeutic class, as they are reluctant with early phase trials.


Target: 5, Approached: 35, Identified: 6

 

Oncology Study


As well as this being a highly popular and competitive therapeutic area, site recruitment has historically proved challenging with this study.


Target: 10, Approached: 40, Identified: 11

 

Oncology, Advanced NHL Tumours


Being a heavily saturated and competitive therapeutic area, identifying and recruiting willing sites was undoubtedly going to be difficult for this trial.


Target: 3, Approached: 36, Identified: 4

Outcome
Across these three studies, PharmaSols achieved a rate of 117% of the global sponsor site identification target.


We approached a total of 111 sites throughout Australia and New Zealand and identified 21 sites, a number that went beyond our original target.


We attribute this success to our dedication and core values. Our process is people-focused, which means we value relationships, collaboration, and always include our personal touch. Through our expert team and established relationships with sites, we can deliver results that ensure a rapid start-up of your study.

Case Studies

Expedited Timelines and Recruitment Success for COVID-19 Vaccine Trial

While the pandemic has slowed down most of the globe, it has increased the demand for rapid solutions within the pharmaceutical industry, with an urgent need to find a vaccine and COVID-19 related treatments and vaccines. Running clinical trials for potential solutions is a vital element in this process.

Read more
High Recruitment: Twice as many patients as global CRO

Faced with a challenging recruitment process, needing to recruit a large number of elderly participants within a tight three-month seasonal recruitment window, a US-based Biotech Company appointed PharmaSols as the NZ CRO for this phase three respiratory clinical trial.

Read more
Rapid start-up: First SIV in less than 35 days

Having previously worked with PharmaSols over a number of trials, the US sponsor knew that the PharmaSols team could deliver on both tight start-up timelines and high recruitment targets. PharmaSols proven record of flexible, rapid, and creative solutions meant we were the ideal CRO partner.

Read more
Creative Solutions for US Biotech Clinical Trial

A US-based Biotech company was seeking a CRO who could successfully recruit a large number of elderly research participants in New Zealand. A challenge that was not only squeezed into a three-month seasonal recruitment window but was also met with issues so unique, there were no established protocols.

Read more
Rapid Start-up and Tight FPI Timeline for US Biotech Clinical Trial

After a sudden decision to expedite their study timelines, a US Biotech company approached PharmaSols in need of a CRO who could successfully achieve a quality rapid start-up within a tight timeline.

Read more
Quick Feasibility for Rare Genetic Trial

A US Biotech company reached out to PharmaSols, to investigate the feasibility of running a trial in New Zealand on participants' stored tissue samples, where consent had been given for further research to identify a rare genetic marker.

Read more